News & Press Releases

Access the latest news about Lipidor, our current projects, publications and collaborations. Thank you for your interest in Lipidor!

Subscribe

January 24, 2024

Lipidor completes SEK 1.7 million sale of animal segment patent

STOCKHOLM, Sweden, 24th January 2024 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that one of the company's patents, previously out-licensed to Emollivet AB, has now been sold to the same party. The sale is aimed at strengthening Lipidor's short term cash position. Since its inception…

December 17, 2021

Lipidor expands clinical program, announces investment in new drug development project against acne vulgaris

STOCKHOLM, 17[th] December 2021 – Lipidor AB (publ) (Nasdaq First North: LIPI) today announces that it has initiated a preclinical program for…

December 9, 2021

Lipidor presents Nomination Committee

STOCKHOLM, 9[th] December 2021 – In accordance with the current nomination committee instructions for Lipidor AB (publ) (Nasdaq First North Growth Market:…

November 25, 2021

Lipidor publishes interim report for period 1 January – 30 September and Q3 2021

STOCKHOLM, Sweden, 25[th] November 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period…

October 29, 2021

Lipidor submits new patent application and expands collaboration with Cannassure using Lipidor’s AKVANO[®] technology for medicinal cannabis products

Stockholm, Sweden, 29 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announced that the collaboration agreement with…

October 19, 2021

Warrant holders exercise all warrants in Lipidor’s incentive program 2018/2021

STOCKHOLM, Sweden, 19 October 2021 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company’s LTI 2018/2021,…

September 27, 2021

Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

STOCKHOLM, Sweden, September 27, 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company’s Phase III clinical…

August 24, 2021

Lipidor publishes interim report for H1 2021

STOCKHOLM, Sweden, 24[th] August 2021: Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period…

July 6, 2021

Summer letter from Lipidor

STOCKHOLM, Sweden, 6 July 2021: CEO Ola Holmlund comments on the year’s progress so far and the recent commercial license agreement with…

July 1, 2021

Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70

STOCKHOLM, Sweden, 30 June 2021: Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that it has signed a licence…

June 8, 2021

Bulletin from the Extraordinary General Meeting of Lipidor AB (publ)

STOCKHOLM, Sweden, 8 June 2021: The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Lipidor (publ) (the “Company”)…